BioSpace News Archive

As of September 30, 2017, cash and cash equivalents totaled $51.2 million.

Record total revenue of $69.0 million, up 26.8% over the same period in 2016.

Portage Biotech plans to distribute as stock dividend, a substantial part of the 6,341,500 common shares it holds in Biohaven Pharma.

The 12-week, pivotal Phase III, randomized, double-blind, placebo-controlled, parallel-dose study will consist of four treatment arms evaluating the efficacy and safety of a once-daily, oral, fixed dose combination pill of 180 mg of bempedoic acid and 10 mg of ezetimibe versus placebo, 180 mg of bempedoic acid alone and 10 mg of ezetimibe alone.

The company held a Grand Opening ceremony on November 4, 2017 for its new Shanghai facility located in “Pharma Valley” in Shanghai Zhangjiang High-Tech Park.

Emerging clinical data confirms the potential for RPL554 to be an important, novel treatment for patients with COPD.

A Certificate of Occupancy for this facility was issued by the City of Portland, Maine on October 30, 2017.

A conference call and webcast will follow at 4:30 p.m. EST (1:30 p.m. PST).

Net Revenue increased 13% to $112.6 million compared to $99.4 million in the same quarter last year.

Total net revenues for the quarter ended September 30, 2017 were $14.3 million.